Esterified estrogens with and without methyltestosterone decrease arterial LDL metabolism in cynomolgus monkeys

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 16, Issue 12, 1996, Pages 1473-1480

  Wagner, Janice D ^a   Zhang, Li ^a   Williams, J Koudy ^a   Register, Thomas C ^a   Ackerman, Dennis M ^b   Wiita, Brinda ^b   Clarkson, Thomas B ^a   Adams, Michael R ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b Solvay Pharmaceuticals Inc   (Netherlands)

Author keywords

androgen; cardiovascular disease; estrogen; menopause; women's health

Indexed keywords

ESTRADIOL; ESTRATEST; ESTRONE; METHYLTESTOSTERONE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; DRUG EFFECT; ESTROGEN THERAPY; FEMALE; ISCHEMIC HEART DISEASE; LIPID PEROXIDATION; LIPOPROTEIN BLOOD LEVEL; LIPOPROTEIN METABOLISM; MACACA; MENOPAUSE; NONHUMAN; PRIORITY JOURNAL;

EID: 0030464756     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.16.12.1473     Document Type: Article

References (57)

1. Stampfer MJ, Colditz GA. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prev Med. 1991;20:47-63.
2. Barrett-Connor E, Bush TL. Estrogen and coronary heart disease in women. JAMA. 1991;265:1861-1867.
3. Burger HG, Hailes J, Menelaus M, Nelson J, Hudson B, Balazs N. The management of persistent menopausal symptoms with oestradiol-testosterone implants: clinical, lipid and hormonal results. Maturitas. 1984;6:351-358.
4. Sherwin BB, Gelfand MM. Differential symptom response to parenteral estrogen and/or androgen administration in the surgical menopause. Am J Obstet Gynecol. 1985;151:153-160.
5. Hickock LR, Toomey C, Speroff L. A comparison of esterified estrogens with and without methyltestosterone: effects on endometrial histology and serum lipoproteins in postmenopausal women. Obstet Gynecol. 1993;82:919-924.
6. Watts NB, Notelovitz M, Timmons MC, Addison WA, Wiita B, Downey LJ. Comparison of oral estrogens and estrogens plus androgen on bone mineral density, menopausal symptoms, and lipid-lipoprotein profiles in surgical menopause. Obstet Gynecol. 1995;85: 529-537.
7. Stampfer MJ, Willett WC, Colditz GA, Speizer FE, Hennekens CH. A prospective study of past use of oral contraceptive agents and risk of cardiovascular diseases. N Engl J Med. 1988;319:1313-1317.
8. Clarkson TB, Shively CA, Morgan TM, Koritnik DR, Adams MR, Kaplan JR. Oral contraceptives and coronary artery atherosclerosis of cynomolgus monkeys. Obstet Gynecol. 1990;75:217-222.
9. Wagner JD, Adams MR, Schwenke DC, Clarkson TB. Oral contraceptive treatment decreases arterial LDL degradation in female cynomolgus monkeys. Circ Res. 1993;72:1300-1307.
10. Hauner H, Stangl K, Burger K, Busch U, Blömer H, Pfeiffer EF. Sex hormone concentrations in men with angiographically assessed coronary artery disease: relationship to obesity and body fat distribution. Klin Wochenschr. 1991;69:664-668.
11. Märin P, Krotkiewski M, Björntorp P. Androgen treatment of middle-aged, obese men: effects on metabolism, muscle and adipose tissues. Eur J Med. 1992;1:329-336.
12. Bagatell CJ, Heiman JR, Matsumoto AM, Rivier JE, Bremner WJ. Metabolic and behavioral effects of high-dose, exogenous testosterone in healthy men. J Clin Endocrinol Metab. 1994;79:561-567.
13. Davis SR, McCloud P, Strauss BJG, Burger H. Testosterone enhances estradiol's effects on postmenopausal bone density and sexuality. Maturitas. 1995;21:227-236.
14. Adams MR, Kaplan JR, Manuck SB, Koritnik DR, Parks JS, Wolfe MS, Clarkson TB. Inhibition of coronary artery atherosclerosis by 17-beta estradiol in ovariectomized monkeys: lack of an effect of added progesterone. Arteriosclerosis. 1990;10:1051-1057.
15. Wagner JD, Clarkson TB, St. Clair RW, Schwenke DC, Shively CA, Adams MR. Estrogen and progesterone replacement therapy reduces LDL accumulation in the coronary arteries of surgically postmenopausal cynomolgus monkeys. J Clin Invest. 1991;88:1995-2002.
16. Wagner JD, St. Clair RW, Schwenke DC, Shively CA, Adams MR, Clarkson TB. Regional differences in arterial low-density lipoprotein metabolism in surgically postmenopausal cynomolgus monkeys: effects of estrogen and progesterone therapy. Arterioscler Thromb. 1992;12:717-726.
17. Allain CC, Poon LS, Chan CSG, Richmond W, Fu PC. Enzymatic determination of total serum cholesterol. Clin Chem. 1974;20: 470-475.
18. Lipid Research Clinics Program. Manual of Laboratory Operations: Lipid and Lipoprotein Analysis. Bethesda, Md: National Institutes of Health, 1974. US Dept of Health, Education, and Welfare publication 75-628.
19. Fossati P, Principe L. Serum triglycerides determined colorimetrically with an enzyme that produces hydrogen peroxide. Clin Chem. 1982;28:2077-2080.
20. Parks JS, Gebre AK. Studies on the effect of dietary fish oil on the physical and chemical properties of low density lipoproteins in cynomolgus monkeys. J Lipid Res. 1991;32:305-315.
21. Auerbach BJ, Parks JS, Applebaum-Bowden D. A rapid and sensitive micro-assay for the enzymatic determination of plasma and lipoprotein cholesterol. J Lipid Res. 1990;31:738-742.
22. Koritnik DR, Rudel LL. Measurement of apolipoprotein A-I concentration in nonhuman primate serum by enzyme-linked immunosorbent assay (ELISA). J Lipid Res. 1983;24:1639-1645.
23. Sorci-Thomas M, Wilson MD, Johnson FL, Williams DL, Rudel LL. Studies on the expression of genes encoding apolipoproteins B100 and B48 and the low density lipoprotein receptor in nonhuman primates. J Biol Chem. 1989;264:9039-9045.
24. Carroll RM, Rudel LL. Lipoprotein separation and low density lipoprotein molecular weight determination using high performance gel-filtration chromatography. J Lipid Res. 1983;24:200-207.
25. Rudel LL, Lee JA, Morris MD, Felts JM. Characterization of plasma lipoproteins separated and purified by agarose column chromatography. Biochem J. 1974;139:89-95.
26. Lowry OH, Rosenbrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951;193:265-275.
27. Schwenke DC, Carew TE. Quantification in vivo of increased LDL content and rate of LDL degradation in the normal rabbit aorta occurring at sites susceptible to early atherosclerotic lesions. Circ Res. 1988;62:699-710.
28. Fraker PJ, Speck JC Jr. Protein and cell membrane iodination with a sparingly soluble chloroamide 1,3,4,6-tetrachloro-3α,6α-diphenyl-glycoluril. Biochem Biophys Res Commun. 1978;80:849-857.
29. Bligh EG, Dyer WJ. A rapid method of total lipid extraction and purification. Can J Biochem Physiol. 1959;37:911-917.
30. Yedgar S, Carew TE, Pittman RC, Beltz WF, Steinberg D. Tissue sites of catabolism of albumin in rabbits. Am J Physiol. 1983;144: E101-E107.
31. Carew TC, Pittman RC, Marchand ER, Steinberg D. Measurement in vivo of irreversible degradation of low-density lipoprotein in the rabbit aorta. Arteriosclerosis. 1984;4:214-224.
32. Folch J, Lees M, Sloane Stanley GH. A simple method for the isolation and purification of total lipids from animal tissues. J Biol Chem. 1957;224:497-509.
33. Can TP, Andresen CJ, Rudel LL. Enzymatic determination of triglyceride, free cholesterol, and total cholesterol in tissue lipid extracts. Clin Biochem. 1993;26:39-42.
34. Yagi K. Lipid peroxides and human diseases. Chem Phys Lipids. 1987;45:337-351.
35. Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem. 1979;95: 351-358.
36. Troy SM, Hicks DR, Parker VD, Jusko WJ, Rofsky HE, Porter RJ. Differences in pharmacokinetics and comparative bioavailability between Premarin® and Estratab® in healthy postmenopausal women. Curr Ther Res. 1994;55:359-372.
37. Rudel LL, Bond MG, Bullock BC. LDL heterogeneity and atherosclerosis in nonhuman primates. Ann N Y Acad Sci. 1985;454: 248-253.
38. Subbiah MTR, Kessel B, Agrawal M, Rajan R, Abplanalp W, Rymaszewski Z. Antioxidant potential of specific estrogens on lipid peroxidation. J Clin Endocrinol Metab. 1993;77:1095-1097.
39. Sack MN, Rader DJ, Cannon RO III. Oestrogen and inhibition of oxidation of low-density lipoproteins in postmenopausal women. Lancet. 1994;343:269-270.
40. Huber LA, Scheffler E, Poll T, Ziegler R, Dresel HA. 17 Beta-estradiol inhibits LDL oxidation and cholesteryl ester formation in cultured macrophages. Free Radic Res Commun. 1990;8:167-173.
41. Witztum JL, Steinberg D. Role of oxidized low density lipoprotein in atherogenesis. J Clin Invest. 1991;88:1785-1792.
42. de Graaf J, Hak-Lemmers HLM, Hectors MPC, Demacker PNM, Hendriks JCM, Stalenhoef AFH. Enhanced susceptibility to in vitro oxidation of the dense low-density lipoprotein subfraction in healthy subjects. Arterioscler Thromb. 1991;11:298-306.
43. Walsh BW, Schiff I, Rosner B, Greenberg L, Ravnikar V, Sacks FM. Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins. N Engl J Med. 1991; 325:1196-1204.
44. Eriksson M, Berglund L, Rudling M, Henriksson P, Angelin B. Effects of estrogen on low density lipoprotein metabolism in males: short-term and long-term studies during hormonal treatment of prostatic carcinoma. J Clin Invest. 1989;84:802-810.
45. Ma PT, Yamamoto T, Goldstein JL, Brown MS. Increased mRNA for low density lipoprotein receptors in livers of rabbits treated with 17α-ethinyl estradiol. Proc Natl Acad Sci USA. 1986;83:792-796.
46. Veldhuis JD, Gwynne JT. Estrogen regulates low density lipoprotein metabolism by cultured swine granulosa cells. Endocrinology. 1985; 117:1321-1327.
47. Manning JM, Campos G, Edwards IJ, Wagner WD, Wagner JD, Adams MR, Parks JS. Effects of hormone replacement modalities on low density lipoprotein composition and distribution in ovariectomized cynomolgus monkeys. Atherosclerosis. 1996;121:217-229.
48. van der Mooren MJ, de Graaf J, Demacker PN, de Haan AF, Rolland R. Changes in the low-density lipoprotein profile during 17β-estradiol-dydrogesterone therapy in postmenopausal women. Metab Clin Exp. 1994;43:799-802.
49. Campos H, Sacks FM, Walsh BW, Schiff I, O'Hanesian MA, Krauss RM. Differential effects of estrogen on low-density lipoprotein subclasses in healthy postmenopausal women. Metabolism. 1993;42: 1153-1158.
50. Campos H, McNamara JR, Wilson PWF, Ordovas JM, Schaefer EJ. Differences in low density lipoprotein subfractions and apolipoproteins in premenopausal and postmenopausal women. J Clin Endocrinol Metab. 1988;67:30-35.
51. Granfone A, Campos H, McNamara JR, Schaefer MM, Lamon-Fava S, Ordovas JM, Schaefer EJ. Effects of estrogen replacement on plasma lipoproteins and apolipoproteins in postmenopausal, dyslipidemic women. Metabolism. 1992;41:1193-1198.
52. McNamara JR, Jenner JL, Zhengling L, Wilson PWF, Schaefer FJ. Change in LDL particle size is associated with change in plasma triglyceride concentration. Arterioscler Thromb. 1992;12:1284-1290.
53. Crouse JR, Parks JS, Schey HM, Kahl FR. Studies of low density lipoprotein molecular weight in human beings with coronary artery disease. J Lipid Res. 1985;26:566-573.
54. Rudel LL, Parks JS, Johnson FL, Babiak J. Low density lipoproteins in atherosclerosis. J Lipid Res. 1986;27:465-474.
55. Stevenson SC, Sawyer JK, Rudel LL. Role of apolipoprotein E on cholesteryl ester-enriched low-density lipoprotein particles in coronary artery atherosclerosis of hypercholesterolemic nonhuman primates. Arterioscler Thromb. 1992;12:28-40.
56. Hazzard WR, Applebaum-Bowden D, Terry JG. Apolipoprotein E: paradoxes abound. In: Gallo LL, ed. Cardiovascular Disease 2. New York, NY: Plenum Press; 1995:57-66.
57. Honoré EK, Williams JK, Adams MR, Ackerman DM, Wagner JD. Methyltestosterone does not diminish the beneficial effects of estrogen replacement therapy on coronary artery reactivity. Menopause. 1996;3:20-26.